Literature DB >> 83295

Binding of aggregated human beta2-microglobulin to surface protein structure in group A, C, and G streptococci.

G Kronvall, E B Myhre, L Björck, I Berggård.   

Abstract

A novel mammalian-microbial "short circuit" has been demonstrated between aggregated human beta2-microglobulin and group A, C, and G streptococci. Bacteria belonging to nine gram-positive and three gram-negative species were tested for binding of radiolabeled beta2-microglobulin. All 10 individual strains of group A streptococci showed a high degree of reactivity with aggregated human beta2-microglobulin. Among 27 group C and 28 group G streptococci, 9 and 6 strains, respectively, were highly reactive, whereas the remaining strains showed a lower, but definite level of beta2-microglobulin binding. Of 11 group B streptococci, 4 were slightly positive. All strains among the other eight species were completely negative. Simultaneous testing of A, C, and G streptococci for immunoglobulin binding showed a lack of correlation between type II and III Fc reactivity and beta2-microglobulin binding. There was no inhibition of uptake of aggregated beta2-microglobulin to reactive strains when excess amounts of human immunoglobulin were added. The beta2-microglobulin-binding surface structure was found to be markedly sensitive to trypsin digestion. The relative trypsin resistance of the immunoglobulin-binding protein in the digestion experiments further demonstrated the dissociation between these two reactivities.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83295      PMCID: PMC422127          DOI: 10.1128/iai.22.1.136-142.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Evolutionary relationship between immunoglobulins and transplantation antigens.

Authors:  P A Peterson; L Rask; K Sege; L Klareskog; H Anundi; L Ostberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin.

Authors:  A Forsgren; J Sjöquist
Journal:  J Immunol       Date:  1966-12       Impact factor: 5.422

5.  Complement fixing and macrophage opsonizing activities associated with beta2 microglobulin.

Authors:  R H Painter; D Yasmeen; S N Assimeh; M D Poulik
Journal:  Immunol Commun       Date:  1974

6.  Further structural studies of the heavy chain of HLA antigens and its similarity to immunoglobulins.

Authors:  C Terhorst; R Robb; C Jones; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

7.  Isolation and properties of a low molecular weight beta-2-globulin occurring in human biological fluids.

Authors:  I Berggård; A G Bearn
Journal:  J Biol Chem       Date:  1968-08-10       Impact factor: 5.157

8.  Immunologic "short circuits".

Authors:  G Kronvall; R C Williams
Journal:  Ann Intern Med       Date:  1969-05       Impact factor: 25.391

9.  Relationships between beta2-microglobulin and alloantigens coded for by the major histocompatibility complexes of the rabbit and the guinea pig.

Authors:  L Björck; R Cigén; B Berggård; B Löw; I Berggård
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

10.  Heterogeneity of nonimmune immunoglobulin Fc reactivity among gram-positive cocci: description of three major types of receptors for human immunoglobulin G.

Authors:  E B Myhre; G Kronvall
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

View more
  27 in total

1.  Collagen VI encodes antimicrobial activity: novel innate host defense properties of the extracellular matrix.

Authors:  Suado M Abdillahi; Selma Balvanović; Maria Baumgarten; Matthias Mörgelin
Journal:  J Innate Immun       Date:  2012-03-02       Impact factor: 7.349

2.  Comparison of albumin receptors expressed on bovine and human group G streptococci.

Authors:  R Raeder; R A Otten; M D Boyle
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

3.  Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli.

Authors:  G S Chhatwal; K T Preissner; G Müller-Berghaus; H Blobel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

4.  Attachment of staphylococci and streptococci on fibronectin, fibronectin fragments, and fibrinogen bound to a solid phase.

Authors:  P Kuusela; T Vartio; M Vuento; E B Myhre
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

5.  Guanidine extraction enhances the binding of human fibrinogen to group-B streptococci.

Authors:  G S Chhatwal; C Lämmler; H Blobel
Journal:  Med Microbiol Immunol       Date:  1984       Impact factor: 3.402

6.  Agglutination of Streptococcus mutans by low-molecular-weight salivary components: effect of beta 2-microglobulin.

Authors:  D Ericson
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Binding of human fibronectin to group A, C, and G streptococci.

Authors:  E B Myhre; P Kuusela
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Surface receptors for serum albumin in group C and G streptococci show three different types of albumin specificity.

Authors:  K Wideback; G Kronvall
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

9.  Further characteristics of beta2-microglobulin binding to oral streptococci.

Authors:  D Ericson; L Björck; G Kronvall
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

10.  Variations in the binding of mammalian fibrinogens to streptococci of different animal origin.

Authors:  C Lämmler; G S Chhatwal; H Blobel
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.